- Home
- FCF vs VRDN Comparison
FCF vs VRDN Comparison
Compare FCF & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCF
- VRDN
- Stock Information
- Founded
- FCF 1934
- VRDN 2006
- Country
- FCF United States
- VRDN United States
- Employees
- FCF N/A
- VRDN N/A
- Industry
- FCF Major Banks
- VRDN Medical Specialities
- Sector
- FCF Finance
- VRDN Health Care
- Exchange
- FCF Nasdaq
- VRDN Nasdaq
- Market Cap
- FCF 1.8B
- VRDN 1.5B
- IPO Year
- FCF N/A
- VRDN N/A
- Fundamental
- Price
- FCF $17.89
- VRDN $18.72
- Analyst Decision
- FCF Buy
- VRDN Strong Buy
- Analyst Count
- FCF 7
- VRDN 11
- Target Price
- FCF $19.00
- VRDN $38.80
- AVG Volume (30 Days)
- FCF 492.9K
- VRDN 894.1K
- Earning Date
- FCF 10-28-2025
- VRDN 08-06-2025
- Dividend Yield
- FCF 3.02%
- VRDN N/A
- EPS Growth
- FCF N/A
- VRDN N/A
- EPS
- FCF 1.30
- VRDN N/A
- Revenue
- FCF $454,628,000.00
- VRDN $305,000.00
- Revenue This Year
- FCF $17.70
- VRDN N/A
- Revenue Next Year
- FCF $8.50
- VRDN $35,092.81
- P/E Ratio
- FCF $13.75
- VRDN N/A
- Revenue Growth
- FCF N/A
- VRDN 5.90
- 52 Week Low
- FCF $13.54
- VRDN $9.90
- 52 Week High
- FCF $19.96
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- FCF 65.54
- VRDN 55.80
- Support Level
- FCF $17.35
- VRDN $18.12
- Resistance Level
- FCF $17.96
- VRDN $20.05
- Average True Range (ATR)
- FCF 0.31
- VRDN 1.02
- MACD
- FCF 0.06
- VRDN -0.02
- Stochastic Oscillator
- FCF 76.83
- VRDN 55.81
About FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).